)
)
)
XM Therapeutics is a Brown University spinoff developing tissue repair and regeneration therapies for chronic disorders where an impaired healing response leads to progressive fibrosis (scarring), inflammation, and hypoxia. Applying cutting edge proteomic and 3D cell culture technologies, XM designs injectable human Extracellular Matrix particles (not a cell therapy). The particles engraft in the affected tissue, modulate the dysfunctional matrix to alter cell response, and thereby reduce fibrosis and improve blood flow and organ function. Proof of therapeutic potential has been shown in two animal species and in two organ systems; heart and skin. In both organs, ECM particles had the same effects of reducing scarring and improving healing. The company is pursuing a partnering enabled business model to target multi-billion-dollar conditions starting with chronic wounds and heart failure. Leadership team is in place. Closing seed round and seeking Series A investors.
Year Founded
2022
Next catalyst (value inflection) update
Completion of large animal model and FDA pre-IND meeting for lead candidate.
Expected time of next catalyst update
Jul-26
City
Providence
Country
United States
Company CEO or top company official
Frank Ahmann
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
Human injectable Extracellular Matrix Particles
Number of Unlicensed Products
4
Therapeutic Area
Multiple Therapeutics
Website
https://www.xmtherapeutics.com
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
